Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
June 29, 2026Journal of the American College of Cardiology

Cardiovascular pharmacogenetic discovery outpaces the evidence justifying routine clinical adoption.

View Full Paper
Ask AI
Bookmark
Share

Why the study?

The pace of genetic discovery has outstripped the evidence justifying clinical adoption, leaving questions regarding which pharmacogenetic variants and contexts can be implemented in practice.

Design

Review

Key result

While significant advances have identified pharmacogenetic markers for cardiovascular therapeutics, the pace of genetic discovery has outstripped the evidence justifying routine clinical adoption.

Authors

DVDeepak VooraGGGeoffrey S. Ginsburg

Discussion

Loading...

Member takes

Overview

Pharmacogenetic markers may guide cardiovascular drug response; leaves open need for prospective outcome trials before routine use.

Key Points

  • This review aims to explore pharmacogenetic variants related to commonly used cardiovascular medications and their implications for personalized therapy.
  • Review of association data for genetic variants related to cardiovascular drugs such as antiplatelet agents, warfarin, statins, beta-blockers, diuretics, and antiarrhythmics.
  • Evaluation of pharmacogenetic marker classes: pharmacokinetic, pharmacodynamic, and underlying disease mechanisms.
  • Identification of contexts for pharmacogenetic testing and potential clinician implementation.
  • Identified major pharmacogenetic variants that impact the effectiveness of several cardiovascular drugs.
  • Highlighted the need for clinical trials to assess the routine application of pharmacogenetic testing.
  • Supported individualized therapeutic approaches based on patients' genetic backgrounds, enabling targeted treatment.

PICO

P
Population
Cardiovascular disease
E
Exposure / Comparator
Pharmacogenetic testing

While the pace of genetic discovery has outstripped clinical evidence, current data support individualized pharmacogenetic testing for certain cardiovascular medications.

Limitations

  • The pace of genetic discovery has outstripped the generation of the evidence justifying its clinical adoption.

Cite This Study

Voora et al. (2012) conducted a review in Cardiovascular disease. Pharmacogenetic testing was evaluated. While significant advances have identified pharmacogenetic markers for cardiovascular therapeutics, the pace of genetic discovery has outstripped the evidence justifying routine clinical adoption.

synapsesocial.com/papers/6a428cf0abd2828dd15b1ae2https://doi.org/10.1016/j.jacc.2012.01.067
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Use of Pharmacogenetic Information in the Treatment of Cardiovascular Disease2016 · 9 citations
  2. 2Pharmacogenomics: Application to the Management of Cardiovascular Disease2011 · 58 citations
  3. 3A systematic review on pharmacogenetics in cardiovascular disease: is it ready for clinical application?2011 · 71 citations
  4. 4Clinical Application of Pharmacogenomics in the Administration of Common Cardiovascular Medications2024 · 3 citations
  5. 5Genetics and pharmacogenetics in the diagnosis and therapy of cardiovascular diseases.2019 · 20 citations